CMS Pay For Off-Label Use Of Avastin In Wet Age-Related Macular Degeneration May Discourage Use
This article was originally published in The Pink Sheet Daily
Executive Summary
Rate based on Avastin's cancer indication puts ophthalmologists in the position of choosing whether to take a loss to administer it to Medicare beneficiaries or get full reimbursement for the more expensive, FDA-approved Lucentis.